NeoGenomics Inc. Common Stock vs Global X Robo Global Robotics & Automation ETF — how do they compare? NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.14B), while Global X Robo Global Robotics & Automation ETF trades at $76 (market cap $2.02B). The key difference: NeoGenomics Inc. Common Stock and Global X Robo Global Robotics & Automation ETF are close in size by market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Global X Robo Global Robotics & Automation ETF for 38 Days on average.
| NEO | ROBO | |
|---|---|---|
Market Cap | $2.14B | $2.02B |
Volume | 2,228,400 | 103,334 |
Sector | Health | Sector/Thematic |
52-Week High | $19.91 | $90.34 |
52-Week Low | $7.19 | $63.04 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $2.44B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.85, down 0.22% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure. The robotics ETF faces mixed sentiment amid AI-driven sector growth but lacks current fundamental data for valuation metrics. Recent news highlights robotics adoption expanding beyond automotive into manufacturing, healthcare, and military applications, though earnings visibility remains limited for underlying holdings.
The outlook for ROBO hinges on broader AI and robotics adoption trends, with potential from labor shortages and military demand, but risks include valuation concerns in tech and cyclical exposure. Investors should monitor earnings from constituent companies for fundamental validation of growth narratives amid neutral oscillator signals and bearish technical momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →